Shanghai-based venture capital firm Lilly Asia Ventures has invested in an $80-million Series C financing round for US biotech firm KSQ Therapeutics. It was also one of the pre-IPO backers of California-based Gritstone Oncology Inc.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
